



Eurofins responds to increased demand for COVID-19 testing at schools with cost-effective testing programmes for the educational sector

19 October 2021

Easy, reliable, high quality and cost-effective testing for SARS-CoV-2 (COVID-19) is critical to help reopen and keep open many aspects of society and business sectors worldwide. Eurofins is working with schools and education authorities to design and implement cost-effective solutions to test this important part of our community regularly and reliably.

Since spring 2021, Eurofins has been supporting schools in Europe and the USA through COVID-19 monitoring programmes, in collaboration with local health and education authorities. Group companies pioneered case studies, early in the pandemic, in schools in the USA and Germany to assess the effectiveness of pooled PCR testing. The findings of these studies have allowed Eurofins to develop customer-focussed, cost-effective testing solutions for schools and universities. Pooled testing is underpinned by the gold standard of COVID-19 PCR testing, but significantly reduces the cost of monitoring programmes by simultaneously testing a group, or 'pool', of samples to detect the presence of SARS-CoV-2. Such pooled testing programmes can be replicated in other settings, such as care facilities and workplaces.

These school monitoring programmes are effective and easy to carry out and have been proven to:

- Quickly identify positive cases from symptomatic and asymptomatic individuals to enable rapid isolation and contact tracing.
- Increase confidence in in-person teaching among school staff and parents.
- Distinguish between seasonal flu and COVID-19 infections and avoid unnecessary isolation measures.

Having ramped up the necessary capacity, Eurofins intends to continue to support communities around the world with innovative and cost-effective COVID-19 testing solutions and expand its partnerships within the education sector to facilitate schooling in safe environments.

Since 2020, Eurofins has reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and services and has carried out over 30 million PCR tests in its own laboratories.

For more information, please visit SAFER@WORKTM or contact:

Investor Relations
Eurofins Scientific SE
E-mail: ir@eurofins.com

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing and in agrosience Contract Research Organisation services. Eurofins is one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in the support of clinical studies, as well as having an emerging global presence in Contract Development and Manufacturing Organisations. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With 55,000 staff across a decentralised and entrepreneurial network of 900 laboratories in over 50 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

The Group's objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.

In 2020, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 30 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments, travel and events during COVID-19.

Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific's management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantees can be made as to their completeness or validity.